1. Canada Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Pivotal Therapeutics Inc.

Pivotal Therapeutics Inc.

PVTTF
Pivotal Therapeutics Inc.US flagOther OTC
0.00
USD
+0.00
- -
172,430.00Market Cap
2010 Y
2011 Y
2012 Y
2013 Y
2014 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
-0.01
-0.06
-0.05
-0.04
-0.06
-0.04
Free Cash Flow per Basic Share
- -
-0.05
-0.04
-0.03
-0.06
-0.01
Dividend per Share
- -
- -
- -
- -
- -
- -
Book Value per Share
-0.01
-0.06
-0.1
-0.13
-0.17
-0.21
Tangible Book Value per Share
0.03
0.04
0.01
-0.01
-0.06
-0.09
Basic Weighted Avg Shares
37
67
79
83
92
95
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
-3,861.27
-935.29
-1,786.82
-924.51
Depreciation Expense
- -
- -
- -
- -
- -
1
Net Income, GAAP
- -
-4
-4
-3
-5
-4
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
-3,861.27
-975.77
-1,755.16
-1,028.49
Working Capital
1
2
- -
1
1
-9
LT Debt
- -
- -
- -
2
6
- -
Total Equity
2
3
1
-1
-4
-8
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
-149.14
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Mar'15
Jun'15
Sep'15
ST Debt
6
7
7
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
93
95
96
Market Capitalization
7
5
5

Working Capital

FRC

•

in mil. unless spec.
Mar'15
Jun'15
Sep'15
Total Current Assets
1
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
7
8
9
Payables & Accruals
1
1
2
ST Debt
6
7
7
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
627.8%
Free Cash Flow
- -
- -
82.42%
Net Income, GAAP
- -
- -
81.69%
Sales/Revenue/Turnover
- -
- -
1.01%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2013
- -
- -
- -
- -
- -
2014
- -
- -
- -
- -
- -
2015
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2013
-0.01
-0.01
-0.01
- -
-0.04
2014
-0.02
-0.02
-0.02
- -
-0.06
2015
-0.01
-0.02
-0.01
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2013
- -
- -
- -
- -
- -
2014
- -
- -
- -
- -
- -
2015
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
Rachelle MacSweeney
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Address
81 Zenway Boulevard Woodbridge ON Canada L4H 0S5
IPO Date
Mar 27, 2012
Website
pivotaltherapeutics.us
Similar Companies
MPX International Corp. (MPXOF)
Assertio Holdings, Inc. (ASRT)
Mountain High Acquisitions Corp. (MYHI)
Greenrose Acquisition Corp. (GNRSW)
MariMed Inc. (MRMD)
Syncom Formulations (India) Limited (SYNCOMF.NS)
Business
Pivotal Therapeutics Inc. (PVTTF) operates as a specialty pharmaceutical company focused on the treatment of cardiovascular disease and overall health through prescription-grade pharmaceuticals for dietary management. The company develops and offers optimized Omega-3 therapies, including products targeted at lipid management and cardiovascular risk reduction; it serves healthcare professionals and patients seeking evidence-based nutritional interventions. Headquartered in Canada and founded prior to its public listing on OTCQX and CSE exchanges, Pivotal Therapeutics conducts operations primarily in North America. No major acquisitions, partnerships, funding rounds, or product launches have been reported for the company in the last 1-2 years.

Company News

APIChatGPT

  • defenseworld.net

    Analyzing Collegium Pharmaceutical (NASDAQ:COLL) and Pivotal Therapeutics (OTCMKTS:PVTTF)

  • defenseworld.net

    Contrasting Nektar Therapeutics (NASDAQ:NKTR) & Pivotal Therapeutics (OTCMKTS:PVTTF)